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Background/aim: Physical function decline in chronic kidney disease (CKD) patients has been a popular area of investigation in the
last decade. It has been shown that lower levels of physical function in CKD results in poor outcomes. Nevertheless, nephrology practice
does not include routine assessment of physical function. The aim of the present study is to elucidate which physical function assessment
tool is better in CKD.
Materials and methods: A total of 148 predialysis CKD patients and 40 healthy controls were included in this cross-sectional singleblind study. CKD patients were further divided into two groups as stage 3 and stage 4/5. A hand dynamometer, the Short Physical
Performance Battery (SPPB), and the Timed Up and Go Test (TUGT) were applied to all study participants.
Results: All physical function tests were significantly different between study and control groups. In multivariate analysis the SPPB (P <
0.001) emerged as an independent variable in CKD group.
Conclusion: The SPPB is a promising, easily applicable, inexpensive, and sensitive tool that can indicate functional decline independent
of age in predialysis CKD patients and can be used in clinical practice to monitor these patients.
Key words: Glomerular filtration rate, hand dynamometer, Short Physical Performance Battery, Timed Up and Go Test

1. Introduction
It is now known that patients with chronic kidney disease
(CKD) have lower levels of physical function, giving rise
to poor physical activity and resulting in poor outcomes.
Impaired physical performance has been associated
with increased hospitalizations as well as morbidity and
mortality in CKD patients (1–7). Functional decline has
been found proportionally related to decrease in estimated
glomerular filtration rate (eGFR) (8). Nevertheless,
nephrology practice does not include assessment of
physical function or an effort to prevent physical function
deterioration in time on a routine basis (9).
Evaluation of physical function in CKD enables
clinicians to identify patients with a high risk of
morbidity/mortality, designing exercise programs to
prevent worsening and provide clinical improvement,
follow patients over time, and realize the deterioration/
improvement of medical conditions and monitor the
effectiveness of therapeutic interventions (10,11).
* Correspondence: ozlem81tasoglu@yahoo.com

For use in clinical practice, assessment tools should be
easily applicable, inexpensive, and sensitive to changes.
Although there are many physical function tests used for
CKD patients in the literature, there is not a clear consensus
on which one is better to use in the clinical setting. The
aim of the present study is therefore to elucidate which
physical function assessment tool is better to use with
CKD patients.
2. Materials and methods
A total of 148 consecutive patients who were admitted
to the nephrology department of a training and research
hospital with a diagnosis of CKD in January–October
2015 and 40 healthy controls were included in this crosssectional study. Healthy controls were chosen from healthy
hospital staff on a voluntary basis. Inclusion criteria for the
patients were age between 18 and 80 years and eGFR of
<60 mL min–1 1.73 m–2 at enrollment. Exclusion criteria
included patients under dialysis treatment, acute kidney
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injury, clinical signs of acute infection during the month
preceding the inclusion, active cancer or liver disease at the
time of evaluation, previous diagnosis of immunological
diseases, hypothyroidism, hyperthyroidism, severe chronic
obstructive pulmonary disease, severe heart failure,
rheumatologic diseases including acute exacerbation of
osteoarthritis, recent malignancy, neuromuscular disease,
immobilization for 1 week or more during the last 3
months, orthopedic surgery during the last 1 year or still
causing pain or functional limitation, inability to walk a
distance of 250 m, and use of immunosuppressive drugs.
Stage 1 and 2 CKD patients (eGFR ≥60 mL min–1 1.73
m–2) were not included owing to the fact that metabolic
complications of CKD usually become more distinct
in stage 3 and over (12). This study was performed in
accordance with the Declaration of Helsinki. Hospital
ethics committee approval was obtained and all patients
provided written informed consent.
Demographic and clinical characteristics of the
participants were recorded. Routine blood tests including
complete blood count and blood biochemical analysis were
performed. Body mass indexes and eGFR were calculated.
Patients were divided into two groups as CKD stage 3
and CKD stage 4 and 5 for further intragroup analyses.
Physical function tests were performed by a blind physical
medicine and rehabilitation specialist at the physical
medicine and rehabilitation department of a training and
research hospital.
CKD stages:
Stage 1: eGFR ≥90 mL min–1 1.73 m–2 with kidney
damage (proteinuria, abnormal urinalysis, biopsy, or
imaging studies).
Stage 2: eGFR: 60–89 mL min–1 1.73 m–2 with kidney
damage (proteinuria, abnormal urinalysis, biopsy, or
imaging studies).
Stage 3: eGFR: 30–59 mL min–1 1.73 m–2.
Stage 4: eGFR: 15–29 mL min–1 1.73 m–2.
Stage 5: eGFR <15 mL min–1 1.73 m–2.
The measurements of grip strength were performed
with a Jamar type hydraulic hand dynamometer (Sammons
Preston, USA) and by the dominant hand using the
American Society of Hand Therapists protocol. The patient
is seated, shoulders are adducted and neutrally rotated, the
elbow is flexed at 90°, the forearm is in a neutral position,
and the wrist is between 0° and 30° dorsiflexion. The mean
of three measurements was used (13). All values were
recorded in kilograms.
The Short Physical Performance Battery (SPPB) was
used to evaluate predominantly lower extremity function.
It consists of three independent parts: chair stands, balance,
and a walk of 2.44 m. Chair stands measure the ability to
stand up and sit down with arms crossed on the chest 5
times. The balance test measures the ability to stand side-
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by-side, semitandem, and tandem each for 10 s. The walk
test measures the fastest time of two usual-pace walk trials
of 2.44 m each. Each part is scored between 0 and 4, with
0 representing an inability to attempt or complete the test
and 4 representing the highest level of performance. The
total score is the sum of these scores and ranges between
0 and 12 (14). The SPPB was developed to evaluate lower
extremity function for the Established Populations for
Epidemiology Research in the Elderly cohort study for use
in gerontoloical populations. In elderly patients the SPPB
is highly predictive of death, hospitalization, and need for
institutional care (15).
The Timed Up and Go Test (TUGT) was used to
measure the time needed to stand up from a chair, walk 3
m, turn around, walk back, and sit down again. It is easy
to perform and valuable for assessing static and dynamic
balance (16).
2.1. Statistical analysis
Analysis was performed using SPSS 20.0 (IBM Corp.,
Armonk, NY, USA). Distribution of continuous variables
was evaluated by Shapiro–Wilk test. Descriptive statistics
were expressed as mean ± standard deviation for continuous
variables and median (minimum–maximum) for discrete
variables. Categorical variables were summarized as
number (n) and percentage (%). The significance of the
difference between the two groups in terms of mean values
was assessed with Student’s t-test and median values with
the Mann–Whitney U test. Chi-square analysis was used
to assess the categorical variables. P < 0.05 was considered
statistically significant.
Variables found to be significantly different between
control and CKD groups (Table 1) were evaluated by
univariate analyses. Variables for which the unadjusted
P-value was <0.10 in logistic regression analysis were
identified as potential risk markers and included in the full
model. The model was reduced using stepwise multivariate
logistic regression analyses and potential markers were
eliminated using likelihood ratio tests. P < 0.05 was
considered statistically significant and the confidence
interval was 95%.
3. Results
Of the 188 participants included in the study, 40 (19 males,
21 females) were healthy controls and 148 (71 males, 77
females) were patients with CKD. Numbers of patients
in each stage were as follows: stage 3 (n = 96), stage 4 (n
= 35), and stage 5 (n = 17). Demographic characteristics
and physical performance tests of the patients and healthy
controls are presented in Table 1. Except sex, all of the
demographic characteristics and physical function tests
were significantly different between study and control
groups (Tables 1 and 2). In univariate analyses, age (P <
0.001), BMI (P < 0.001), measurement of grip strength (P
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Table 1. Demographic characteristics of the patients.
Control group
n = 40

CKD group
n = 148

P

39.1 ± 9.3 (24–66)

59.1 ± 11.4 (20–78)

<0.001*

Male/female, n (%)

19 (47.5)/21 (52.5)

71(48)/77(52)

0.958

Height, mean±SD

166.77 ± 7.63

162.39 ± 8.97

0.005*

Weight, mean±SD

73.43 ± 12.47

78.27 ± 14.15

0.031*

BMI, mean±SD

26.43 ± 4.37

29.65 ± 4.75

<0.001*

Age, mean ± SD (min–max)
Sex

*:P < 0.05, significant. CKD: Chronic kidney disease, BMI: body mass index, SPPB: Short Physical Performance
Battery, TUGT: Timed Up and Go Test.
Table 2. Physical performance test results of the patients.
Control group
n = 40

CKD group
n = 148

P

Male

39.55 + 9.18

33.59 + 7.72

0.005*

Female

27.36 + 6.17

19.84 + 6.18

<0.001*

Male Chair stands

4 (3–4)

4 (2–4)

0.001*

Balance test

4 (4–4)

4 (2–4)

0.012*

Walk test

4 (4–4)

4 (2–4)

0.001*

Total

12 (11–12)

11 (8–12)

<0.001*

Female Chair stands

4 (4–4)

3 (1–4)

<0.001*

Balance test

4 (4–4)

4 (0–4)

0.001*

Walk test

4 (3–4)

3 (1–4)

<0.001*

Total

12 (11–12)

9 (4–12)

<0.001*

Male

7.19 (4.88–10.16)

9.08 (5.28–14.59)

<0.001*

Female

7.70 (6.20–10.16)

10.84 (6.89–24.57)

<0.001*

Dynamometer, mean ± SD

SPPB, median (min–max)

TUGT, mean ± SD

*:P < 0.05, significant. SD: Standard deviation, CKD: chronic kidney disease, SPPB: Short Physical Performance
Battery, TUGT: Timed Up and Go Test.

< 0.001), SPPB (P < 0.001), and TUGT (P < 0.001) were
statistically significant. In multiple logistic regression
analyses, age (P < 0.001), BMI (P = 0.03), and SPPB (P
< 0.001) emerged as independent variables in the study
group (Table 3).
The patients in the study group were further analyzed
to demonstrate the differences in physical function tests
according to different CKD stages. Patients were divided
into two groups according to CKD stages as stage 3 and
stage 4/5. Except sex, there were no statistically significant
differences between the demographic characteristics

of the groups (Table 4). There were also no significant
differences regarding the physical function tests (Table 5).
4. Discussion
The results of the present study demonstrated that the SPPB
is a useful tool to assess physical function in CKD patients
regardless of age and BMI. On the other hand, grip strength
measurement and TUGT seem not to be as specific/sensitive
as the SPPB for the evaluation of physical function in CKD.
Physical performance decline in CKD is a new area of
investigation that has started to be discussed in the last 7
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Table 3. Results of univariate and multivariate regression models.
Univariate analysis

Multivariate analysis

OR (95% CI)

P

OR (95% CI)

P

Age

0.86 (0.82–0.90)

<0.001*

0.90 (0.85–0.95)

<0.001*

BMI

0.83 (0.76–0.92)

<0.001*

0.86 (075–0.98)

0.03*

Dynamometer

1.07 (1.03–1.11)

<0.001*

1.01 (0.94–1.07)

0.75

SPPB total

14.64 (4.45–48.11)

<0.001*

15.05 (2.92–77.46)

0.001*

TUGT

0.39 (0.27–0.55)

<0.001*

0.83 (0.52–1.33)

0.45

*:P < 0.05, significant. BMI: Body mass index, SPPB: Short Physical Performance Battery, TUGT: Timed
Up and Go Test.
Table 4. Demographic characteristics of CKD patients in stages 3 and 4/5.
CKD stage 3
n = 96

CKD stage 4/5
n = 52

P

59.54 ± 10.92

58.25 ± 12.37

0.514

Male/female, n (%)

56 (58.3)/40(41.7)

15(28.8)/37(71.2)

0.001*

Height, mean ± SD

163.21 ± 8.93

160.86 ± 8.91

0.128

Weight, mean ± SD

79.81 ± 13.81

75.43 ± 14.46

0.072

BMI, mean ± SD

29.97 ± 4.79

29.06 ± 4.66

0.272

Age, mean ± SD (min–max)
Sex

*:P < 0.05 significant. SD: Standard deviation, CKD: chronic kidney disease, BMI: body mass index.
Table 5. Physical performance test results of CKD patients in stages 3 and 4/5.
CKD stage 3
n = 96

CKD stage 4/5
n = 52

P

Male

33.99 ± 7.51

32.12 ± 8.58

0.411

Female

20.31 ± 6.51

19.33 ± 5.84

0.490

Male Chair stands

3 (2–4)

4 (2–4)

0.641

Balance test

4 (2–4)

4 (2–4)

0.842

Walk test

4 (2–4)

4 (2–4)

0.646

Total

11 (8–12)

11 (8–12)

0.436

Female Chair stands

3 (1–4)

3 (1–4)

0.638

Balance test

4 (0–4)

4 (1–4)

0.655

Walk test

3 (1–4)

3 (1–4)

0.092

Total

9 (4–12)

9 (4–12)

0.372

Male

9.27 (5.28–14.59)

8.79 (5.96–12.40)

0.607

Female

10.43 (6.89–16.50)

11.37 (7.83–24.57)

0.092

Dynamometer, mean ± SD

SPPB, median (min–max)

TUGT, mean ± SD

SD: Standard deviation, CKD: chronic kidney disease, SPPB: Short Physical Performance Battery, TUGT:
Timed Up and Go Test.
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or 8 years. In 2008 Brodin et al. evaluated grip strength,
knee extensor strength, TUGT, and rising from a 45-cm
chair without using the hands in 55 predialysis patients
with eGFR of ≤20 mL min–1 1.73 m–2. According to their
results, there were no associations between eGFR and grip
strength, knee extensor strength, and TUGT, but eGFR
and rising from a 45-cm chair without using the hands
were inversely correlated. For every 1 mL min–1 1.73 m–2
decrease in eGFR, the odds ratio was 1.5 times higher
that the patient would not be able to rise from the chair.
The results of that study are in concordance with ours as
grip strength and TUGT were found useless for predicting
the physical function decline in predialysis patients.
Furthermore, as rising from a chair predominantly
represents lower extremity function and is a part of the
SPPB, worse results with decreasing eGFR also support
our results (17).
Later on, in 2009, Okuno et al. similarly investigated
the association between eGFR and physical function
by using grip strength, functional reach, one leg stance,
tandem stance, 5-m walk, and TUGT in 109 patients ≥65
years. Multiple linear regression analysis results suggested
that eGFR was significantly associated with functional
reach and tandem stance, but not TUGT and grip strength.
Again, these results also confirm ours (18).
A total of 385 ambulatory, stroke-free CKD stage 2–4
patients were included in a study by Roshanravan et al.
(7) in 2013. Hand-grip strength, usual gait speed, TUGT,
and 6-min walking test were evaluated. All test results
were 30%–39% lower in that study population compared
to healthy adults. In contrast, hand-grip strength was not
impaired. Moreover, the results of that study revealed that
gait speed and TUGT more strongly predicted 3-year
mortality in CKD than kidney function or more commonly
measured serum biomarkers. These results, with worse
lower extremity performance measures and relatively
preserved upper extremity performance measures, are in
concordance with our results to a certain extent.
In another study by Hiraki et al. in 2013, 120 predialysis
stage 2–5 CKD patients were evaluated. Knee extensor
muscle strength, single-leg stance time, maximum gait
speed, and even hand-grip strength (in contrast to similar
studies) were all decreased with the progression of CKD
and all physical function tests showed positive correlations
with eGFR. Additionally, the authors found significant
decline in physical function tests of stage 4–5 CKD patients
compared to stage 2–3 CKD patients (19). In that study the
superiority of one test over another was not evaluated.
The abovementioned studies have contradictory results
and the tests seem inadequate unless assisted by more than
one physical function assessment tool.
In 2011 the SPPB was used to measure physical
performance in 375 hemodialysis patients for the first

time. The association of SPPB and eGFR was not evaluated
but older age, black race, diabetes mellitus, and peripheral
arterial disease were found to be associated with poorer
scores on the SPPB in hemodialysis patients. Older age was
already known to be associated with worse SPPB scores,
so these results were not surprising. Furthermore, as this
study included only patients on hemodialysis, the results
cannot be generalized to all CKD patients (20). In another
study performed with 486 patients ≥65 years of age in
2012, eGFR was found to be independently associated
with SPPB total score (21). A more comprehensive
analysis including 1111 CKD patients of all stages was
performed in 2013 and worse SPPB score was found to
be independently associated with the severity of renal
dysfunction (12). Finally, in the CAN-FIT study published
in 2015, 217 nondialysis patients with CKD of stages 4
and 5 were evaluated with the SPPB. Of the 217 patients
56% had scores of <10, whereas 44% had scores of ≥ 10
and the mean score was 8.04. The SPPB was found to be
worse in older patients, females, and diabetics but was
not correlated with eGFR (22). Although the SPPB was
demonstrated to be useful to evaluate physical function in
CKD in all of the studies above and was moreover found
to be independently associated with renal function in 2 of
them (12,21), it has not been compared to other physical
function measurement tools and none of the studies
introduced the independency of the SPPB from age in
CKD.
The results of our study revealed that the SPPB can be
used to interpret the functional status of CKD patients
independent of age. Moreover, comparison of the SPPB
with other popularly used physical function assessment
tools was performed and the superiority of the SPPB was
demonstrated. On the other hand, the present study could
not demonstrate a difference between SPPB scores of
different CKD stages. The similarity of physical function
test results between all CKD stages was surprising for
the authors. The patients were admitted to the study
in consecutive order and the physical medicine and
rehabilitation specialist who performed the tests was
trained, single, and blind. However, these tests were not
developed specifically for CKD patients, so they may not
be sensitive enough to demonstrate minimal changes
between the groups. This may be an explanation. Moreover,
this may also be associated with the low patient numbers
in the groups, especially in stage 5.
The most important limitation of this study is the
cross-sectional design, which precludes to follow the
changes in SPPB results over time. Moreover, the number
of stage 5 patients (n = 17) was low and the number of all
patients was also relatively low for such a prevalent disease.
Apart from the design and study group limitations, there
is an important handicap about the control group. Due
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to the sample from which the control group was selected
(healthy volunteers from the hospital staff), the mean age
and the mean BMI of the control group were significantly
lower. This may be estimated as an unintended bias and
the results should be assessed with caution. Moreover,
laboratory analysis results of the patients that may
influence the functional status were not studied. Future
longitudinal studies of large patient groups and matched
controls are needed.
In conclusion, the SPPB, assessing lower extremity
function in three dimensions (rising from a chair
repetitively, stance, and walking speed), is both a more

comprehensive and more sensitive tool for evaluating
functional decline in CKD patients compared with the other
evaluation methods. It seems to be worse in CKD patients
independent of age. Although the SPPB is a tool originally
developed for geriatric physical function assessment and
results get worse with age, the demonstration of the SPPB
as a physical function assessment tool independent of age
in CKD patients is important. As a result the SPPB is a
promising, easily applicable, inexpensive, and sensitive
tool that can indicate functional decline independent of
age in CKD patients and it can be used in clinical practice
to monitor these patients easily.
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